Working… Menu

Study of Metformin Pharmacogenetics in Twins

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01869621
Recruitment Status : Completed
First Posted : June 5, 2013
Last Update Posted : December 3, 2014
Information provided by (Responsible Party):
Tore B. Stage, University of Southern Denmark

Brief Summary:
The trough concentration of metformin will be examined in monozygotic and dizygotic twins. Current twin study will determine the total weight of genetics on the trough concentration of metformin.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: Metformin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Relation Between Heritability and the Trough Concentration of Metformin in Plasma Under Steady-state in Twins
Study Start Date : April 2013
Actual Primary Completion Date : March 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Metformin
6 days treatment with metformin
Drug: Metformin
6 days treatment with metformin to steady-state

Primary Outcome Measures :
  1. Heritability [ Time Frame: After 6 days of metformin treatment ]
    The trough concentrations of metformin in twin pairs will be used to determine the effect of heritability on metformin trough concentrations. This will give insight to the weight that genetic factors have on metformin pharmacokinetics at steady-state.

Secondary Outcome Measures :
  1. Single nucleotide polymorphisms (SNPs) [ Time Frame: After 6 days treatment with metformin ]
    The effect of SNPs on trough metformin concentration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18-40 years
  • Both twins has to be included
  • Dizygotic twin pairs has to be same sex
  • Informed consent given
  • Healthy condition

Exclusion Criteria:

  • Chronical/daily alcohol abuse
  • Hypersensitivity to metformin
  • Ingestion of drugs containing topiramate or x-ray contrast fluids
  • For women: Positive pregnancy test/breastfeeding at the beginning of the trial. No use of safe anticonceptives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01869621

Layout table for location information
Clinical Pharmacology
Odense C, Denmark, 5000
Sponsors and Collaborators
University of Southern Denmark

Layout table for additonal information
Responsible Party: Tore B. Stage, MSc Pharm, University of Southern Denmark Identifier: NCT01869621     History of Changes
Other Study ID Numbers: AKF-383
2012-005179-15 ( EudraCT Number )
First Posted: June 5, 2013    Key Record Dates
Last Update Posted: December 3, 2014
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypoglycemic Agents
Physiological Effects of Drugs